2022-07-18T00:00:00.000+10:00
Ongoing

Ascent 03

Ascent 03
Breast cancer

A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumors do express PD-L1 (Ascent 03 GS-US-592-6238)

A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumors do express PD-L1 (Ascent 03 GS-US-592-6238)

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Breast cancer

Study Phase

III

Trial Identifiers

Registration number: NCT05382299

https://clinicaltrials.gov/study/NCT05382299

GenesisCare Location(s)

GenesisCare North Shore 

GenesisCare North Shore  :::
Principal Investigator(s)

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.